“Because AN0128 effectively targets inflammation in a topical preparation, it is a promising treatment against atopic dermatitis,” said Dr Karl Beutner, chief medical officer at Anacor.
The study plans to enroll 200 patients between the ages of 2 and 17 years with moderate atopic dermatitis, and researchers will assess the safety and effectiveness of the treatment.
AN0128 is designed to inhibit the release of pro-inflammatory cytokines, without affecting the normal immune response. It has demonstrated potent anti-inflammatory activity in preclinical models of inflammation. This activity gives the compound the potential to treat a number of diseases. Anacor has also conducted phase I/II trials of AN0128 in acne and psoriasis and will evaluate further studies in these indications.
Past studies of AN0128 have shown promise, particularly in moderate AD. Results from a phase IIa study showed that 51 % of patients with atopic dermatitis treated with AN0128 were judged to have skin that was “clear” or “almost clear,” as compared with 37% of patients treated with the vehicle treatment.
Atopic dermatitis is a disease affecting approximately 15 million Americans and is characterized by a chronic rash with accompanying inflammation and infection. It is most common in children, with an estimated 20% affected by the condition.